Herpes simplex virus encephalitis (HSE) is the leading cause of non-epidemic encephalitis
in the developed world and, despite antiviral therapy, mortality and morbidity is high. The …

Herpes simplex viruses (HSV) types 1 and 2 are ubiquitous infections in humans. They
cause orofacial and genital herpes with occasional severe complications. HSV2 also …

Peptide vaccines have advantages in easy fabrication and high safety, but their
effectiveness is hampered by the poor immunogenicity of the epitopes themselves. Herein …

The aim of our minireview is to provide a brief overview of the diagnosis, clinical aspects,
treatment options, management, and current literature available regarding herpes simplex …

Oncolytic herpes simplex viruses (oHSV) preferentially replicate in cancer cells while
inducing antitumor immunity, and thus, they are often referred to as in situ cancer vaccines …

Effective experimental prophylactic vaccines against viral pathogens such as herpes
simplex virus type 1 (HSV-1) have been shown to protect the host through T and/or B …

The study of Ag-specific lymphocytes has been a key advancement in immunology over the
past few decades. The development of multimerized probes containing Ags, peptide: MHC …

Genital herpes (GH) is a common sexually transmitted disease, which is primarily caused by
herpes simplex virus type 2 (HSV-2), and continues to be a global health concern. Although …

Herpes Simplex virus types 1 and 2 (HSV-1 and-2) are prevalent lifelong infections globally,
causing serious complications and predisposing to HIV acquisition. HSV-1 infection of the …

The study of antigen-specific lymphocytes has been a key advancement in immunology over
the past few decades. One innovation allowing for this type of research was the …